Pharmacogenomic Considerations in Opioid Therapy

Authors

Alexa Zeiger, Cedars Sinai Medical Network
John Andraos, Cedars Sinai Medical Network
Ajay Sharma, Chapman UniversityFollow
Moom R. Roosan, Chapman UniversityFollow

Document Type

Article

Publication Date

3-15-2022

Abstract

Opioids are among the most common medications used in the treatment of pain, and they carry many serious risks if used inappropriately. Pharmacogenomic considerations can impact a patient’s treatment plan for chronic pain, as CYP polymorphisms may interfere with nonsteroidal anti-inflammatory drugs, tricyclic antidepressants, and opioids. In particular, CYP2D6 polymorphisms may play a considerable part in the safety and efficacy of codeine, hydrocodone, and tramadol, as outlined in the Clinical Pharmacogenetic Implementation Consortium (CPIC) guideline on opioids. Based on current research, the CPIC recently updated its guidance on opioid use and interactions with CYP2D6, OPRM1, and COMT polymorphisms. Greater pharmacist understanding of CYP polymorphisms can lead to safer opioid prescribing and better outcomes for patients receiving pain management.

Comments

This article was originally published in U.S. Pharmacist, volume 47, issue 3, in 2022.

Recommended Citation

Zeiger A, Andraos J, Sharma A, Roosan MR. Pharmacogenomic considerations in opioid therapy. US Pharm. 2022;47(3):HS7-HS12. https://www.uspharmacist.com/article/pharmacogenomic-considerations-in-opioid-therapy

Copyright

Jobson Medical Information LLC